Log in

Relevant bibliographies by topics / Drug delivery to brain / Journal articles

To see the other types of publications on this topic, follow the link: Drug delivery to brain.

Journal articles on the topic 'Drug delivery to brain'

Author: Grafiati

Published: 28 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Drug delivery to brain.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Rahman, Ruman, Emma Campbell, Henry Brem, Monica Pearl, Jordan Green, Miroslaw Janowski, Piotr Walczak, et al. "SCIDOT-08. CHILDREN’S BRAIN TUMOUR DRUG DELIVERY CONSORTIUM (CBTDDC)." Neuro-Oncology 21, Supplement_6 (November 2019): vi274. http://dx.doi.org/10.1093/neuonc/noz175.1149.

Full text

Abstract:

Abstract INTRODUCTION The brain tumour community has seen significant progress in the discovery of new therapeutic targets and anticancer drugs. Unfortunately, advances in how to deliver drugs to the brain lag behind. The blood-brain barrier restricts the entry of many small-molecule drugs and nearly all large molecule drugs that have been developed to treat brain disorders. METHODS Following an international CNS drug delivery workshop in 2016, we were awarded funding from Children with Cancer UK to launch the Children’s Brain Tumour Drug Delivery Consortium (CBTDDC; www.cbtddc.org; @cbtddc). RESULTS The CBTDDC launched in 2017 (in Europe and the US) to raise awareness of the challenge of drug delivery in childhood brain tumours, and to initiate and strengthen research collaborations to accelerate the development of drug delivery systems. We ran a Workshop on Drug Delivery to the Brain, attracting 52 delegates from the UK, Belgium, Spain and Portugal. We liaised with UK-based funders over the drug delivery agenda, and with UK policy makers. In the US, we jointly organised the SIGN2019 meeting and we are currently liaising with the leads of Project ‘All In’ DIPG about how we can lend our support to this project. As of June 2019, 150 individuals have registered with the consortium, representing researchers, clinicians, charities, patient groups and industry. These stakeholders represent 70 research institutions, covering 15 countries (France, UK, Italy, Sweden, The Netherlands, USA, Greece, Germany, Belgium, Cuba, Denmark, Spain, Portugal, Israel and Egypt). We host a freely accessible online collaborative research database, containing the details of over 70 researchers. CONCLUSION We believe that collaboration between clinicians and multi-disciplinary researchers is vital to solving the brain tumour drug delivery challenge. We hope to raise awareness of the CBTDDC, and to extend our invitation for collaborators to join the consortium, through SCIDOT’s unrivalled drug delivery platform.

APA, Harvard, Vancouver, ISO, and other styles

2

Airan, Raag. "Stimulating brain drug delivery." Science Translational Medicine 12, no. 564 (October 7, 2020): eabe8119. http://dx.doi.org/10.1126/scitranslmed.abe8119.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Bodor, Nicholas, and Peter Buchwald. "Brain-Targeted Drug Delivery." American Journal of Drug Delivery 1, no. 1 (2003): 13–26. http://dx.doi.org/10.2165/00137696-200301010-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Hoag, Hannah. "Drug delivery: Brain food." Nature 510, no. 7506 (June 2014): S6—S7. http://dx.doi.org/10.1038/510s6a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Belmaker, R. H., and G. Agam. "Deep Brain Drug Delivery." Brain Stimulation 6, no. 3 (May 2013): 455–56. http://dx.doi.org/10.1016/j.brs.2012.05.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Jiang, Xinguo. "Brain Drug Delivery Systems." Pharmaceutical Research 30, no. 10 (August 7, 2013): 2427–28. http://dx.doi.org/10.1007/s11095-013-1148-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kumar, Pankaj, Varun Garg, and Neeraj Mittal. "Nose to Brain Drug Delivery System: A Comprehensive Review." Drug Delivery Letters 10, no. 4 (November 20, 2020): 288–99. http://dx.doi.org/10.2174/2210303110999200526123006.

Full text

Abstract:

Nose to brain drug delivery system is an interesting approach to deliver a drug directly in the brain through the nose. Intranasal drug delivery is very beneficial because it avoids first-pass metabolism and achieves a greater concentration of drugs in the central nervous system (CNS) at a low dose. This delivery system is used for the treatment of various neurological disorders such as Parkinson's disease, Alzheimer's disease, schizophrenia, dementia, brain cancer, etc. To treat such types of diseases, different formulations like nanoparticles (NPs), microemulsions, in situ gel, etc. can be used depending on the physiochemical properties of the drug. In this review, some essential characteristics related to the delivery of nose to the brain and their possible obstacles are underlined, which include anatomy and physiology of nose to brain delivery. This review also summarizes innovations from the past three to five years.

APA, Harvard, Vancouver, ISO, and other styles

8

Joshi, Shailendra, Phillip M. Meyers, and Eugene Ornstein. "Intracarotid Delivery of Drugs." Anesthesiology 109, no. 3 (September 1, 2008): 543–64. http://dx.doi.org/10.1097/aln.0b013e318182c81b.

Full text

Abstract:

The major efforts to selectively deliver drugs to the brain in the past decade have relied on smart molecular techniques to penetrate the blood-brain barrier, whereas intraarterial drug delivery has drawn relatively little attention. Meanwhile, rapid progress has been made in the field of endovascular surgery. Modern endovascular procedures can permit highly targeted drug delivery by the intracarotid route. Intracarotid drug delivery can be the primary route of drug delivery or it could be used to facilitate the delivery of smart neuropharmaceuticals. There have been few attempts to systematically understand the kinetics of intracarotid drugs. Anecdotal data suggest that intracarotid drug delivery is effective in the treatment of cerebral vasospasm, thromboembolic strokes, and neoplasms. Neuroanesthesiologists are frequently involved in the care of such high-risk patients. Therefore, it is necessary to understand the applications of intracarotid drug delivery and the unusual kinetics of intracarotid drugs.

APA, Harvard, Vancouver, ISO, and other styles

9

Bahadur, Shiv, Nidhi Sachan, Ranjit K. Harwansh, and Rohitas Deshmukh. "Nanoparticlized System: Promising Approach for the Management of Alzheimer’s Disease through Intranasal Delivery." Current Pharmaceutical Design 26, no. 12 (May 6, 2020): 1331–44. http://dx.doi.org/10.2174/1381612826666200311131658.

Full text

Abstract:

Alzheimer's disease (AD) is a neurodegenerative brain problem and responsible for causing dementia in aged people. AD has become most common neurological disease in the elderly population worldwide and its treatment remains still challengeable. Therefore, there is a need of an efficient drug delivery system which can deliver the drug to the target site. Nasal drug delivery has been used since prehistoric times for the treatment of neurological disorders like Alzheimer's disease (AD). For delivering drug to the brain, blood brain barrier (BBB) is a major rate limiting factor for the drugs. The desired drug concentration could not be achieved through the conventional drug delivery system. Thus, nanocarrier based drug delivery systems are promising for delivering drug to brain. Nasal route is a most convenient for targeting drug to the brain. Several factors and mechanisms need to be considered for an effective delivery of drug to the brain particularly AD. Various nanoparticlized systems such as nanoparticles, liposomes, exosomes, phytosomes, nanoemulsion, nanosphere, etc. have been recognized as an effective drug delivery system for the management of AD. These nanocarriers have been proven with improved permeability as well as bioavailability of the anti-Alzheimer’s drugs. Some novel drug delivery systems of anti-Alzheimer drugs are under investigation of different phase of clinical trials. Present article highlights on the nanotechnology based intranasal drug delivery system for the treatment of Alzheimer’s disease. Furthermore, consequences of AD, transportation mechanism, clinical updates and recent patents on nose to brain delivery for AD have been discussed.

APA, Harvard, Vancouver, ISO, and other styles

10

Deepti R. Damle, Dr. Archana D. Kajale, Dr. Madhuri A. Channawar, and Dr. Shilpa R. Gawande. "A review: Brain specific delivery." GSC Biological and Pharmaceutical Sciences 13, no. 2 (November 30, 2020): 068–79. http://dx.doi.org/10.30574/gscbps.2020.13.2.0349.

Full text

Abstract:

The overall prevalence rate for CNS pathology has demonstrated that approximately more than one billion people are undergoing from disorders of central nervous system. The most distressing fact about delivery of drugs to the CNS is the presence of blood brain barrier that have a tendency to impair the drug distribution and denotes the major impediment for the development of CNS drugs. Neuropeptides and many drugs which are hydrophilic in nature possibly will encompass the intricacy while passing the blood brain barrier. The net amount of delivered drug (medicinal agent) and its capability to gain access to the pertinent target sites are the main considering points for CNS drug development. Brain targeted drug delivery to the brain is valuable in the diseases of brain. (Alzheimer’s diseases, meningitis, brain abscess, epilepsy, multiple sclerosis, neuromylitis optica, sleeping disorders etc). Whereby high concentration can be gained with lesser side effects that occur because of release of drugs. The simplest method of targeting to brain is to obtain a therapeutic. Brain targeting systems to remain in the brain region by crossing BBB and hence significantly helps in increasing therapeutic activity. There is an increasing attraction towards brain targeting and sue to its immense application in the treatment of various CNS diseases because mostly drugs are unable to cross the BBB. This review article discuss one of the novel technology “nanotechnology” and other aspects that has been developed to target the brain and possess various clinical benefits such as reduced drug dose, less side effects, non-invasive routed, and better patient compliance.

APA, Harvard, Vancouver, ISO, and other styles

11

Masserini, Massimo. "Nanoparticles for Brain Drug Delivery." ISRN Biochemistry 2013 (May 21, 2013): 1–18. http://dx.doi.org/10.1155/2013/238428.

Full text

Abstract:

The central nervous system, one of the most delicate microenvironments of the body, is protected by the blood-brain barrier (BBB) regulating its homeostasis. BBB is a highly complex structure that tightly regulates the movement of ions of a limited number of small molecules and of an even more restricted number of macromolecules from the blood to the brain, protecting it from injuries and diseases. However, the BBB also significantly precludes the delivery of drugs to the brain, thus, preventing the therapy of a number of neurological disorders. As a consequence, several strategies are currently being sought after to enhance the delivery of drugs across the BBB. Within this review, the recently born strategy of brain drug delivery based on the use of nanoparticles, multifunctional drug delivery systems with size in the order of one-billionth of meters, is described. The review also includes a brief description of the structural and physiological features of the barrier and of the most utilized nanoparticles for medical use. Finally, the potential neurotoxicity of nanoparticles is discussed, and future technological approaches are described. The strong efforts to allow the translation from preclinical to concrete clinical applications are worth the economic investments.

APA, Harvard, Vancouver, ISO, and other styles

12

Bonferoni, Maria, Silvia Rossi, Giuseppina Sandri, Franca Ferrari, Elisabetta Gavini, Giovanna Rassu, and Paolo Giunchedi. "Nanoemulsions for “Nose-to-Brain” Drug Delivery." Pharmaceutics 11, no. 2 (February 17, 2019): 84. http://dx.doi.org/10.3390/pharmaceutics11020084.

Full text

Abstract:

The blood–brain barrier (BBB) plays a fundamental role in protecting the brain from toxic substances and therefore also controls and restricts the entry of therapeutic agents. The nasal administration of drugs using the nose-to-brain pathway allows direct drug targeting into the brain, avoiding the first-pass effect and bypassing the BBB. Through the nasal route, the drug can access the brain directly along the trigeminal and olfactory nerves, which are located in the upper part of the nasal cavity. Nanoemulsions are formulations belonging to the field of nanomedicine. They consist of emulsions (commonly oil in water) stabilized by one or more surfactants—and eventually co-surfactants—delivered in droplets of small dimensions (sizes of 100–300 nm or less) with a high surface area. A mucoadhesive polymer such as chitosan can be added to the formulation to impair rapid nasal clearance. Nanoemulsions represent promising formulations to deliver drugs directly into the brain through the intranasal route. Therefore, they can be used as a possible alternative to oral administration, avoiding problems such as low solubility in water, poor bioavailability, enzymatic degradation and slow onset of action. This review focuses the present situation in literature regarding the use of nanoemulsions for nose-to-brain targeting, with particular attention to recent publications. Nasal nanoemulsions appear to be effective, non-invasive and safe drug delivery systems to achieve brain targeting for the treatment of neurological diseases.

APA, Harvard, Vancouver, ISO, and other styles

13

Singh, Ruchita, Charles Brumlik, Mandar Vaidya, and Abhishek Choudhury. "A Patent Review on Nanotechnology-Based Nose-to-Brain Drug Delivery." Recent Patents on Nanotechnology 14, no. 3 (October 26, 2020): 174–92. http://dx.doi.org/10.2174/1872210514666200508121050.

Full text

Abstract:

Background: Current cerebral drug delivery to the brain and Cerebrospinal Fluid (CSF) is limited by the Blood-Brain Barrier (BBB) or the blood-blood Cerebrospinal Fluid (CSF) barrier. The popular, non-invasive, intranasal delivery provides an exciting route for topical and systemic applications. For example, intranasal drug delivery of Central Nervous System (CNS) drugs can be designed to pass the BBB barrier via the nose-to-brain pathways. Recent nanotechnology research and patenting focus mainly on overcoming typical limitations including bioavailability, transport, BBB penetration, targeted delivery, controlled release rate and controlled degradation. Objective: The aim of the present study was to assess the state-of-the-art of nose-to-brain drug delivery systems and the role of nanotechnology in targeted delivery for the treatment of CNS and related therapeutic conditions. Methods: Patent and related searches were made with analytics to explore and organize nanotech work in intranasal drug delivery to the brain. Technical advancements were mapped by API, formulation and performance criteria. Patents and published patent applications were searched with concept tables of keywords, metadata (e.g., assignee) and patent classes (e.g., International Patent Classes and Cooperative Patent Classes). Results: The reviewed patents and published applications show a focus on formulations and therapeutic indications related to the nano-based nose-to-brain drug delivery. The main patented materials were surface modifiers, delivery systems and excipients. Conclusion: Surface modified nanoparticles can greatly improve drug transport and bioavailability of drugs, particularly higher molecular weight drugs. The most commonly used surface modifiers were chitosan, lectin and cyclodextrin-cross-linker complex. Nanoformulations of herbal drugs could increase drug bioavailability and reduce toxicity. Biotechnology-related drug delivery approaches such as monoclonal antibodies and genetically engineered proteins (molecular Trojan horses) deliver large molecule therapeutics.

APA, Harvard, Vancouver, ISO, and other styles

14

Giunchedi, Paolo, Elisabetta Gavini, and Maria Cristina Bonferoni. "Nose-to-Brain Delivery." Pharmaceutics 12, no. 2 (February 6, 2020): 138. http://dx.doi.org/10.3390/pharmaceutics12020138.

Full text

Abstract:

Nose-to-brain delivery represents a big challenge. In fact there is a large number of neurological diseases that require therapies in which the drug must reach the brain, avoiding the difficulties due to the blood–brain barrier (BBB) and the problems connected with systemic administration, such as drug bioavailability and side-effects. For these reasons the development of nasal formulations able to deliver the drug directly into the brain is of increasing importance. This Editorial regards the contributions present in the Special Issue “Nose-to-Brain Delivery”.

APA, Harvard, Vancouver, ISO, and other styles

15

Froelich, Anna, Tomasz Osmałek, Barbara Jadach, Vinam Puri, and Bozena Michniak-Kohn. "Microemulsion-Based Media in Nose-to-Brain Drug Delivery." Pharmaceutics 13, no. 2 (February 2, 2021): 201. http://dx.doi.org/10.3390/pharmaceutics13020201.

Full text

Abstract:

Nose-to-brain drug delivery has recently attracted enormous attention as an alternative to other delivery routes, including the most popular oral one. Due to the unique anatomical features of the nasal cavity, drugs administered intranasally can be delivered directly to the central nervous system. The most important advantage of this approach is the ability to avoid the blood–brain barrier surrounding the brain and blocking the entry of exogenous substances to the central nervous system. Moreover, selective brain targeting could possibly avoid peripheral side effects of pharmacotherapy. The challenges associated with nose-to-brain drug delivery are mostly due to the small volume of the nasal cavity and insufficient drug absorption from nasal mucosa. These issues could be minimized by using a properly designed drug carrier. Microemulsions as potential drug delivery systems offer good solubilizing properties and the ability to enhance drug permeation through biological membranes. The aim of this review is to summarize the current status of the research focused on microemulsion-based systems for nose-to-brain delivery with special attention to the most extensively investigated neurological and psychiatric conditions, such as neurodegenerative diseases, epilepsy, and schizophrenia.

APA, Harvard, Vancouver, ISO, and other styles

16

Lamsam, Layton, Eli Johnson, Ian D. Connolly, Max Wintermark, and Melanie Hayden Gephart. "A review of potential applications of MR-guided focused ultrasound for targeting brain tumor therapy." Neurosurgical Focus 44, no. 2 (February 2018): E10. http://dx.doi.org/10.3171/2017.11.focus17620.

Full text

Abstract:

Magnetic resonance–guided focused ultrasound (MRgFUS) has been used extensively to ablate brain tissue in movement disorders, such as essential tremor. At a lower energy, MRgFUS can disrupt the blood-brain barrier (BBB) to allow passage of drugs. This focal disruption of the BBB can target systemic medications to specific portions of the brain, such as for brain tumors. Current methods to bypass the BBB are invasive, as the BBB is relatively impermeable to systemically delivered antineoplastic agents. Multiple healthy and brain tumor animal models have suggested that MRgFUS disrupts the BBB and focally increases the concentration of systemically delivered antitumor chemotherapy, immunotherapy, and gene therapy. In animal tumor models, combining MRgFUS with systemic drug delivery increases median survival times and delays tumor progression. Liposomes, modified microbubbles, and magnetic nanoparticles, combined with MRgFUS, more effectively deliver chemotherapy to brain tumors. MRgFUS has great potential to enhance brain tumor drug delivery, while limiting treatment toxicity to the healthy brain.

APA, Harvard, Vancouver, ISO, and other styles

17

Walker, W. "Drug delivery to brain tumors." Bulletin of Mathematical Biology 58, no. 6 (November 1996): 1047–74. http://dx.doi.org/10.1016/s0092-8240(96)00025-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Lo, E. "Drug delivery to damaged brain." Brain Research Reviews 38, no. 1-2 (December 2001): 140–48. http://dx.doi.org/10.1016/s0165-0173(01)00083-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Walker, Wynn L., and Julian Cook. "Drug delivery to brain tumors." Bulletin of Mathematical Biology 58, no. 6 (November 1996): 1047–74. http://dx.doi.org/10.1007/bf02458383.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Blakeley, Jaishri. "Drug delivery to brain tumors." Current Neurology and Neuroscience Reports 8, no. 3 (May 2008): 235–41. http://dx.doi.org/10.1007/s11910-008-0036-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Upadhyay, Ravi Kant. "Drug Delivery Systems, CNS Protection, and the Blood Brain Barrier." BioMed Research International 2014 (2014): 1–37. http://dx.doi.org/10.1155/2014/869269.

Full text

Abstract:

Present review highlights various drug delivery systems used for delivery of pharmaceutical agents mainly antibiotics, antineoplastic agents, neuropeptides, and other therapeutic substances through the endothelial capillaries (BBB) for CNS therapeutics. In addition, the use of ultrasound in delivery of therapeutic agents/biomolecules such as proline rich peptides, prodrugs, radiopharmaceuticals, proteins, immunoglobulins, and chimeric peptides to the target sites in deep tissue locations inside tumor sites of brain has been explained. In addition, therapeutic applications of various types of nanoparticles such as chitosan based nanomers, dendrimers, carbon nanotubes, niosomes, beta cyclodextrin carriers, cholesterol mediated cationic solid lipid nanoparticles, colloidal drug carriers, liposomes, and micelles have been discussed with their recent advancements. Emphasis has been given on the need of physiological and therapeutic optimization of existing drug delivery methods and their carriers to deliver therapeutic amount of drug into the brain for treatment of various neurological diseases and disorders. Further, strong recommendations are being made to develop nanosized drug carriers/vehicles and noninvasive therapeutic alternatives of conventional methods for better therapeutics of CNS related diseases. Hence, there is an urgent need to design nontoxic biocompatible drugs and develop noninvasive delivery methods to check posttreatment clinical fatalities in neuropatients which occur due to existing highly toxic invasive drugs and treatment methods.

APA, Harvard, Vancouver, ISO, and other styles

22

Pandey, Manisha, Hira Choudhury, Rohit Kumar Verma, Viney Chawla, Subrat Kumar Bhattamisra, Bapi Gorain, Maria Abdul Ghafoor Raja, and Muhammad Wahab Amjad. "Nanoparticles Based Intranasal Delivery of Drug to Treat Alzheimer’s Disease: A Recent Update." CNS & Neurological Disorders - Drug Targets 19, no. 9 (December 31, 2020): 648–62. http://dx.doi.org/10.2174/1871527319999200819095620.

Full text

Abstract:

Alzheimer Association Report (2019) stated that the 6th primary cause of death in the USA is Alzheimer’s Disease (AD), which leads to behaviour and cognitive impairment. Nearly 5.8 million peoples of all ages in the USA have suffered from this disease, including 5.6 million elderly populations. The statistics of the progression of this disease is similar to the global scenario. Still, the treatment of AD is limited to a few conventional oral drugs, which often fail to deliver an adequate amount of the drug in the brain. The reduction in the therapeutic efficacy of an anti-AD drug is due to poor solubility, existence to the blood-brain barrier and low permeability. In this context, nasal drug delivery emerges as a promising route for the delivery of large and small molecular drugs for the treatment of AD. This promising pathway delivers the drug directly into the brain via an olfactory route, which leads to the low systemic side effect, enhanced bioavailability, and higher therapeutic efficacy. However, few setbacks, such as mucociliary clearance and poor drug mucosal permeation, limit its translation from the laboratory to the clinic. The above stated limitation could be overcome by the adaption of nanoparticle as a drug delivery carrier, which may lead to prolong delivery of drugs with better permeability and high efficacy. This review highlights the latest work on the development of promising Nanoparticles (NPs) via the intranasal route for the treatment of AD. Additionally, the current update in this article will draw the attention of the researcher working on these fields and facing challenges in practical applicability.

APA, Harvard, Vancouver, ISO, and other styles

23

Koziara, J. M., P. R. Lockman, D. D. Allen, and R. J. Mumper. "The Blood-Brain Barrier and Brain Drug Delivery." Journal of Nanoscience and Nanotechnology 6, no. 9 (September 1, 2006): 2712–35. http://dx.doi.org/10.1166/jnn.2006.441.

Full text

Abstract:

The present report encompasses a thorough review of drug delivery to the brain with a particular focus on using drug carriers such as liposomes and nanoparticles. Challenges in brain drug delivery arise from the presence of one of the strictest barriers in vivo—the blood-brain barrier (BBB). This barrier exists at the level of endothelial cells of brain vasculature and its role is to maintain brain homeostasis. To better understand the principles of brain drug delivery, relevant knowledge of the blood-brain barrier anatomy and physiology is briefly reviewed. Several approaches to overcome the BBB have been reviewed including the use of carrier systems. In addition, strategies to enhance brain drug delivery by specific brain targeting are discussed.

APA, Harvard, Vancouver, ISO, and other styles

24

Lesniak, Maciej S. "Novel Advances in Drug Delivery to Brain Cancer." Technology in Cancer Research & Treatment 4, no. 4 (August 2005): 417–28. http://dx.doi.org/10.1177/153303460500400409.

Full text

Abstract:

The therapy of brain tumors has been limited by a lack of effective methods of drug delivery to the brain. Systemic administration is often associated with toxic side effects and ultimately fails to achieve therapeutic concentrations within a tumor. An attractive strategy that has gained importance in brain tumor therapy has relied on local and controlled delivery of chemotherapeutic agents by biodegradable polymers. This technique allows direct exposure of tumor cells to a therapeutic agent for a prolonged period of time and has been shown to prolong the survival of patients with malignant brain tumors. The use of polymers for local drug delivery greatly expands the spectrum of drugs available for the treatment of malignant brain tumors. This review discusses the rationale for local drug delivery, describes the development of currently available polymer-based therapeutic agents, and highlights examples of promising non-polymer based drug delivery methods for use in the treatment of malignant brain tumors.

APA, Harvard, Vancouver, ISO, and other styles

25

Pardridge, William M. "Brain drug delivery and blood–Brain barrier transport." Drug Delivery 1, no. 2 (January 1993): 83–101. http://dx.doi.org/10.3109/10717549309022762.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Pardridge, William M. "Brain drug delivery and blood–brain barrier transport." Drug Delivery 3, no. 2 (January 1996): 99–115. http://dx.doi.org/10.3109/10717549609031180.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Kulkarni, Abhijeet D., Harun M. Patel, Sanjay J. Surana, Veena S. Belgamwar, and Chandrakantsing V. Pardeshi. "Brain–blood ratio: implications in brain drug delivery." Expert Opinion on Drug Delivery 13, no. 1 (September 22, 2015): 85–92. http://dx.doi.org/10.1517/17425247.2016.1092519.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Pardridge, William M. "CSF, blood-brain barrier, and brain drug delivery." Expert Opinion on Drug Delivery 13, no. 7 (April 11, 2016): 963–75. http://dx.doi.org/10.1517/17425247.2016.1171315.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Aderibigbe, Blessing Atim, and Tobeka Naki. "Chitosan-Based Nanocarriers for Nose to Brain Delivery." Applied Sciences 9, no. 11 (May 30, 2019): 2219. http://dx.doi.org/10.3390/app9112219.

Full text

Abstract:

In the treatment of brain diseases, most potent drugs that have been developed exhibit poor therapeutic outcomes resulting from the inability of a therapeutic amount of the drug to reach the brain. These drugs do not exhibit targeted drug delivery mechanisms, resulting in a high concentration of the drugs in vital organs leading to drug toxicity. Chitosan (CS) is a natural-based polymer. It has unique properties such as good biodegradability, biocompatibility, mucoadhesive properties, and it has been approved for biomedical applications. It has been used to develop nanocarriers for brain targeting via intranasal administration. Nanocarriers such as nanoparticles, in situ gels, nanoemulsions, and liposomes have been developed. In vitro and in vivo studies revealed that these nanocarriers exhibited enhanced drug uptake to the brain with reduced side effects resulting from the prolonged contact time of the nanocarriers with the nasal mucosa, the surface charge of the nanocarriers, the nano size of the nanocarriers, and their capability to stretch the tight junctions within the nasal mucosa. The aforementioned unique properties make chitosan a potential material for the development of nanocarriers for targeted drug delivery to the brain. This review will focus on chitosan-based carriers for brain targeting.

APA, Harvard, Vancouver, ISO, and other styles

30

Kumar, Bhumika, Mukesh Pandey, Faheem H. Pottoo, Faizana Fayaz, Anjali Sharma, and P. K. Sahoo. "Liposomes: Novel Drug Delivery Approach for Targeting Parkinson’s Disease." Current Pharmaceutical Design 26, no. 37 (October 26, 2020): 4721–37. http://dx.doi.org/10.2174/1381612826666200128145124.

Full text

Abstract:

Parkinson’s disease is one of the most severe progressive neurodegenerative disorders, having a mortifying effect on the health of millions of people around the globe. The neural cells producing dopamine in the substantia nigra of the brain die out. This leads to symptoms like hypokinesia, rigidity, bradykinesia, and rest tremor. Parkinsonism cannot be cured, but the symptoms can be reduced with the intervention of medicinal drugs, surgical treatments, and physical therapies. Delivering drugs to the brain for treating Parkinson’s disease is very challenging. The blood-brain barrier acts as a highly selective semi-permeable barrier, which refrains the drug from reaching the brain. Conventional drug delivery systems used for Parkinson’s disease do not readily cross the blood barrier and further lead to several side-effects. Recent advancements in drug delivery technologies have facilitated drug delivery to the brain without flooding the bloodstream and by directly targeting the neurons. In the era of Nanotherapeutics, liposomes are an efficient drug delivery option for brain targeting. Liposomes facilitate the passage of drugs across the blood-brain barrier, enhances the efficacy of the drugs, and minimize the side effects related to it. The review aims at providing a broad updated view of the liposomes, which can be used for targeting Parkinson’s disease.

APA, Harvard, Vancouver, ISO, and other styles

31

Caffo, Maria, Giuseppe Raudino, and Gerardo Caruso. "Nanotechnology and Brain Tumors Drug Delivery." Recent Patents on Nanomedicine 3, no. 1 (July 1, 2013): 26–36. http://dx.doi.org/10.2174/1877912311303010005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Le Bras, Alexandra. "Local drug delivery to brain tumor." Lab Animal 49, no. 1 (December 18, 2019): 18. http://dx.doi.org/10.1038/s41684-019-0453-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

C. Ligade, Pushpanjali, Kisan R. Jadhav, and Vilasrao J. Kadam. "Brain Drug Delivery System: An Overview." Current Drug Therapy 5, no. 2 (May 1, 2010): 105–10. http://dx.doi.org/10.2174/157488510791065085.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Dong, Xiaowei. "Current Strategies for Brain Drug Delivery." Theranostics 8, no. 6 (2018): 1481–93. http://dx.doi.org/10.7150/thno.21254.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Greig, Nigel H. "Optimizing drug delivery to brain tumors." Cancer Treatment Reviews 14, no. 1 (March 1987): 1–28. http://dx.doi.org/10.1016/0305-7372(87)90048-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Comoglu, Tansel, Sema Arisoy, and Zeynep Akkus. "Nanocarriers for Effective Brain Drug Delivery." Current Topics in Medicinal Chemistry 17, no. 13 (April 4, 2017): 1490–506. http://dx.doi.org/10.2174/1568026616666161222101355.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Vyas, Tushar, Aliasgar Shahiwala, Sudhanva Marathe, and Ambikanandan Misra. "Intranasal Drug Delivery for Brain Targeting." Current Drug Delivery 2, no. 2 (April 1, 2005): 165–75. http://dx.doi.org/10.2174/1567201053586047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Wang, Paul P., James Frazier, and Henry Brem. "Local drug delivery to the brain." Advanced Drug Delivery Reviews 54, no. 7 (October 2002): 987–1013. http://dx.doi.org/10.1016/s0169-409x(02)00054-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Campbell, Dr Emma, Prof David Walker, Dr Ruman Rahman, Prof Richard Grundy, Prof Henry Brem, Dr Monica Pearl, Dr Jordan Green, et al. "Children’s Brain Tumour Drug Delivery Consortium." Neuro-Oncology 20, suppl_5 (October 2018): v355. http://dx.doi.org/10.1093/neuonc/noy130.050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Celia, Christian, Donato Cosco, Donatella Paolino, and Massimo Fresta. "Nanoparticulate devices for brain drug delivery." Medicinal Research Reviews 31, no. 5 (February 16, 2010): 716–56. http://dx.doi.org/10.1002/med.20201.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Rapoport, S. I. "Peptide Drug Delivery to the Brain." Neurology 42, no. 5 (May 1, 1992): 1131. http://dx.doi.org/10.1212/wnl.42.5.1131-c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Wei, Xiaoli, Xishan Chen, Man Ying, and Weiyue Lu. "Brain tumor-targeted drug delivery strategies." Acta Pharmaceutica Sinica B 4, no. 3 (June 2014): 193–201. http://dx.doi.org/10.1016/j.apsb.2014.03.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Pardridge, William M. "Preface: Overview of brain drug delivery." Advanced Drug Delivery Reviews 15, no. 1-3 (July 1995): 1–3. http://dx.doi.org/10.1016/0169-409x(95)00002-o.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Hanley, Daniel F. "Peptide drug delivery to the brain." Electroencephalography and Clinical Neurophysiology 86, no. 2 (February 1993): 143. http://dx.doi.org/10.1016/0013-4694(93)90094-c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Brewster, Marcus E. "Noninvasive drug delivery to the brain." Neurobiology of Aging 10, no. 5 (September 1989): 638–39. http://dx.doi.org/10.1016/0197-4580(89)90161-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Alam, M. Intakhab, Sarwar Beg, Abdus Samad, Sanjula Baboota, Kanchan Kohli, Javed Ali, Alka Ahuja, and M. Akbar. "Strategy for effective brain drug delivery." European Journal of Pharmaceutical Sciences 40, no. 5 (August 2010): 385–403. http://dx.doi.org/10.1016/j.ejps.2010.05.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Mhambi, Sinaye, David Fisher, Moise B. Tchoula Tchokonte, and Admire Dube. "Permeation Challenges of Drugs for Treatment of Neurological Tuberculosis and HIV and the Application of Magneto-Electric Nanoparticle Drug Delivery Systems." Pharmaceutics 13, no. 9 (September 15, 2021): 1479. http://dx.doi.org/10.3390/pharmaceutics13091479.

Full text

Abstract:

The anatomical structure of the brain at the blood–brain barrier (BBB) creates a limitation for the movement of drugs into the central nervous system (CNS). Drug delivery facilitated by magneto-electric nanoparticles (MENs) is a relatively new non-invasive approach for the delivery of drugs into the CNS. These nanoparticles (NPs) can create localized transient changes in the permeability of the cells of the BBB by inducing electroporation. MENs can be applied to deliver antiretrovirals and antibiotics towards the treatment of human immunodeficiency virus (HIV) and tuberculosis (TB) infections in the CNS. This review focuses on the drug permeation challenges and reviews the application of MENs for drug delivery for these diseases. We conclude that MENs are promising systems for effective CNS drug delivery and treatment for these diseases, however, further pre-clinical and clinical studies are required to achieve translation of this approach to the clinic.

APA, Harvard, Vancouver, ISO, and other styles

48

Semyachkina-Glushkovskaya, Oxana V., Arkady S. Abdurashitov, Elena I. Saranceva, Eketerina G. Borisova, Alexander A. Shirokov, and Nikita V. Navolokin. "Blood–brain barrier and laser technology for drug brain delivery." Journal of Innovative Optical Health Sciences 10, no. 05 (September 2017): 1730011. http://dx.doi.org/10.1142/s1793545817300117.

Full text

Abstract:

Here, we discuss an important problem in medicine as development of effective strategies for brain drug delivery. This problem is related to the blood–brain barrier (BBB), which is a “customs” controlling the entrance of different molecules from blood into the brain protecting the normal function of central nervous system (CNS). We show three interfaces of anatomical side of BBB and two functional types of BBB — physical and transporter barriers. Although this protective mechanism is essential for health of CNS, it also creates a hindrance to the entry of drugs into the brain. The BBB was discovered over 100 years ago but till now, there is no effective methods for brain drug delivery. There are more than 70 approaches for overcoming BBB including physical, chemical and biological techniques but all of these tools have limitation to be widely used in clinical practice due to invasiveness, challenge in performing, very costly or limitation of drug concentration.Photodynamic therapy (PDT) is usual clinical method of surgical navigation for the resection of brain tumor and anti-cancer therapy. Nowadays, the application of PDT is considered as a potential promising tool for brain drug delivery via opening of BBB. Here, we show the first successful experimental results in this field discussing the adventures and disadvantages of PDT-related BBB disruption as well as alternatives to overcome these limitations and possible mechanisms with new pathways for brain clearance via glymphatic and lymphatic systems.

APA, Harvard, Vancouver, ISO, and other styles

49

Chen, Hong, Cherry C. Chen, Camilo Acosta, Shih-Ying Wu, Tao Sun, and Elisa E. Konofagou. "A New Brain Drug Delivery Strategy: Focused Ultrasound-Enhanced Intranasal Drug Delivery." PLoS ONE 9, no. 10 (October 3, 2014): e108880. http://dx.doi.org/10.1371/journal.pone.0108880.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Arora, Deepshi, Shailendra Bhatt, Manish Kumar, Hari D. C. Vattikonda, Yugam Taneja, Vishal Jain, Veenu Joshi, and Chaitanya C. Gali. "Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer’s disease." Current Pharmaceutical Design 26, no. 27 (August 25, 2020): 3281–99. http://dx.doi.org/10.2174/1381612826666200331085854.

Full text

Abstract:

Background: Alzheimer is the primary cause of death in the various countries that affects wide strata of the population. The treatment of it is restricted to a few conventional oral medications that act only superficially. It is evident that the delivery of a drug to the brain across the blood-brain barrier is challenging as the BBB is armed with several efflux transporters like the P-glycoprotein as well as nasal mucociliary clearance adds up leading to decreased concentration and reduced therapeutic efficacy. Considering these, the intranasal IN route of drug administration is emerging as an alternative route for systemic delivery of a drug to the brain. The intranasal (IN) administration of lipid nanoparticles loaded with cerebroactive drugs showed promise in treating various neurodegenerative diseases, since the nasal route allows the direct nose to brain delivery by means of solid lipid nanoparticles (SLN’s). The tailoring of intranasal lipid particulate drug delivery systems is a pleasing approach to facilitate uptake of therapeutic agents at the desired site of action, particularly when a free drug has poor pharmacokinetics/ biodistribution (PK/BD) or significant off-site toxicities. Objectives: 1) In this review, key challenges and physiological mechanisms regulating intranasal brain delivery in Alzheimer’s disease, ex vivo studies, pharmacokinetics parameters including brain uptake and histopathological studies are thoroughly discussed. : 2) A thorough understanding of the in vivo behaviour of the intranasal drug carriers will be the elusive goal. : 3) The article emphasizes to drag the attention of the research community working in the intranasal field towards the challenges and hurdles of the practical applicability of intranasal delivery of cerebroactive drugs. Method: Various electronic databases, journals like nanotechnology and nanoscience, dove press are reviewed for the collection and compilation of data. Results: From in vivo biodistribution studies, pharmacokinetics parameters, and gamma scintigraphy images of various drugs, it is speculated that intranasal lipid particulates drug delivery system shows better brain targeting efficiency for various CNS disorders in comparison to other routes. Conclusion: Various routes are explored for the delivery of drugs to increase bioavailability in the brain for CNS disorders but the intranasal route shows better results that pave the way for success in the future if properly explored.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!